Seikagaku Signs Marketing Agreement for OA Treatment

Seikagaku and Eisai entered into an agreement to co-develop and co-market the SI-613 therapeutic agent to treat knee osteoarthritis in South Korea. This follows a similar agreement between the companies, signed earlier this year, addressing the market in China.

Eisai Korea will acquire exclusive marketing rights for SI-613 in South Korea...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us